CORREALE, MICHELE
 Distribuzione geografica
Continente #
NA - Nord America 3.246
EU - Europa 2.737
AS - Asia 2.304
Continente sconosciuto - Info sul continente non disponibili 386
SA - Sud America 368
AF - Africa 73
OC - Oceania 2
Totale 9.116
Nazione #
US - Stati Uniti d'America 3.168
SG - Singapore 932
IE - Irlanda 643
CN - Cina 617
RU - Federazione Russa 556
SE - Svezia 368
BR - Brasile 299
UA - Ucraina 276
HK - Hong Kong 248
DE - Germania 202
IT - Italia 189
VN - Vietnam 175
FR - Francia 174
IN - India 94
FI - Finlandia 80
AT - Austria 66
BD - Bangladesh 59
GB - Regno Unito 56
CZ - Repubblica Ceca 43
CA - Canada 38
TR - Turchia 38
IQ - Iraq 25
NL - Olanda 23
AR - Argentina 22
MX - Messico 21
ZA - Sudafrica 21
PK - Pakistan 20
ES - Italia 17
PL - Polonia 14
PH - Filippine 13
TN - Tunisia 13
JP - Giappone 12
EC - Ecuador 11
VE - Venezuela 10
UZ - Uzbekistan 9
EG - Egitto 8
KE - Kenya 8
LT - Lituania 7
PE - Perù 7
BE - Belgio 6
CL - Cile 6
CO - Colombia 6
DZ - Algeria 6
MA - Marocco 6
OM - Oman 6
AZ - Azerbaigian 5
CR - Costa Rica 5
ID - Indonesia 5
JM - Giamaica 5
AE - Emirati Arabi Uniti 4
HN - Honduras 4
IR - Iran 4
JO - Giordania 4
NP - Nepal 4
PY - Paraguay 4
SA - Arabia Saudita 4
TH - Thailandia 4
MY - Malesia 3
BG - Bulgaria 2
BH - Bahrain 2
CI - Costa d'Avorio 2
EU - Europa 2
HT - Haiti 2
IL - Israele 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
MK - Macedonia 2
NG - Nigeria 2
PS - Palestinian Territory 2
PT - Portogallo 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BF - Burkina Faso 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
HR - Croazia 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
ML - Mali 1
MU - Mauritius 1
NI - Nicaragua 1
NO - Norvegia 1
PR - Porto Rico 1
RO - Romania 1
RS - Serbia 1
Totale 8.729
Città #
San Jose 805
Dublin 643
Ashburn 437
Singapore 422
Hong Kong 244
Nyköping 233
Beijing 201
Chandler 187
Jacksonville 172
Dallas 159
Santa Clara 123
Munich 103
Lauterbourg 102
New York 78
Dearborn 72
Nanjing 61
Princeton 61
Los Angeles 60
Vienna 59
Moscow 55
Ho Chi Minh City 54
The Dalles 48
Wilmington 45
Hanoi 44
Helsinki 42
Frankfurt am Main 36
Seattle 31
Boardman 30
Brno 28
Turku 25
Nanchang 23
Falkenstein 22
Pune 22
São Paulo 20
London 19
Atlanta 18
Rome 18
Guangzhou 17
San Mateo 17
Hillsboro 15
Nuremberg 15
Olomouc 15
Tianjin 15
Brooklyn 14
Des Moines 14
Shanghai 14
Johannesburg 13
Palermo 13
San Francisco 13
Assago 12
Chennai 12
Council Bluffs 12
Düsseldorf 12
Warsaw 12
Jiaxing 11
Shenyang 11
Toronto 11
Da Nang 10
Mumbai 10
Amsterdam 9
Changsha 9
Foggia 9
Haiphong 9
Hangzhou 9
Milan 9
Montreal 9
Boston 8
Jinan 8
Nairobi 8
Orem 8
Renton 8
Tashkent 8
Tokyo 8
Tunis 8
Washington 8
Baghdad 7
Denver 7
Dhaka 7
Kunming 7
Lund 7
Naples 7
Stevenage 7
Woodbridge 7
Ann Arbor 6
Bari 6
Brussels 6
Chicago 6
Gesualdo 6
Hebei 6
Mexico City 6
Paris 6
Philadelphia 6
Shenzhen 6
Acerra 5
Belo Horizonte 5
Buffalo 5
Curitiba 5
Karachi 5
Ningbo 5
Norwalk 5
Totale 5.376
Nome #
Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding. 158
How to Assess Pulmonary Circulation and Right Heart Chambers in Systemic Sclerosis Patients? 148
Alcohol-induced cardiac disease 142
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 140
"PAFIYAMA" syndrome; further evidence on a novel clinical entity 135
EXPRESS: Don't stop at first glance; pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension 134
Cardiopulmonary exercise test predicts right heart catheterization 127
Delirium in heart failure 127
Typical Takotsubo syndrome and McConnell's phenomenon: What else lies beneath? 123
Influence of Heart Rate on Left and Right Ventricular Longitudinal Strain in Patients with Chronic Heart Failure 123
Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability 119
Chronic thromboembolic pulmonary hypertension. 117
Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry 117
Liver disease and heart failure: Back and forth 116
Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia 114
Biomarkers in cardiorenal syndrome 114
Inferior ST-Elevation Acute Myocardial Infarction or an Inferior-Lead Brugada-like Electrocardiogram Pattern Associated With the Use of Pregabalin and Quetiapine? 112
Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma. 110
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis 110
New Targets in Heart Failure Drug Therapy 109
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure 108
Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy 108
Liver disease and heart failure: an uptodate 108
Recurrent Tako-Tsubo cardiomyopathy apparently induced by opposite triggers 107
Fenofibrate and Dyslipidemia: Still a Place in Therapy? 106
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis 105
Novel AKAP9 mutation and long QT syndrome in a patient with torsades des pointes 102
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure 102
"ischemic" ST elevation in a woman with left ventricular hypertrophy 101
Cardiac contractility modulation in left ventricular systolic dysfunction: trick or treat? 99
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction 98
Redefining biomarkers in heart failure 97
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan 97
Tako-Tsubo cardiomyopathy recurrence in an elderly woman firstly diagnosed with acute myocardial infarction: How many cold cases to be reclassified? 96
Advanced heart failure: non-pharmacological approach 95
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: Where do we stand? 95
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 95
Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry 93
Echocardiographic score for prediction of pulmonary hypertension at catheterization: The Daunia Heart Failure Registry 93
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure 93
SAT0325 Nailfold capillaroscopic changes in patients with idiopathic and systemic sclerosis-related pulmonary arterial ipertension 92
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 92
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone 92
Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use? 90
The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic 90
COMPASS vs PEGASUS approach in a comparative budget impact analysis 89
Delirium in heart failure 89
Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease 88
Effects of Sacubitril/Valsartan on the Renal Resistance Index 87
Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry 87
Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation 86
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 86
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management 84
HIV-associated pulmonary arterial hypertension: from bedside to the future 82
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization 81
Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure 81
Biomarker profiles that differentiate type-1 and type 2 myocardial infarction 80
The thromboembolism in COVID-19: the unsolved problem 79
Impact of Frailty on Outcome of Older Patients With Non-ST Elevation Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention 78
Tako-Tsubo cardiomyopathy or allergic acute coronary syndrome: that is the question. 76
Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction 75
Flow Mediated Dilation in Systemic Sclerosis: Association with clinical findings, capillaroscopic patterns and endothelial circulating markers 73
Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis 71
Atrial paced rhythm and heart rate-dependent worsening of left atrial and ventricular function 71
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 70
Gastrointestinal bleeding and coagulation disorders in a patient with left-ventricular assist device 70
Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches 70
Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy 69
The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction 68
Combined peripheral and central ultrasound for the diagnosis of PAH-SSc patients 67
Relationship between the strain measures of left atrial function and heart failure worsening 67
Left ventricular reverse remodeling after combined ARNI and SGLT2 therapy in heart failure patients with reduced or mildly reduced ejection fraction 67
Utility of Clustering in Mortality Risk Stratification in Pulmonary Hypertension 67
Switch to Gliflozins and Biventricular Function Improvement in Patients with Chronic Heart Failure and Diabetes Mellitus 67
Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register 66
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study) 66
Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies 66
Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan 65
Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets 64
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 64
Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender 64
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 63
SGLT2 Inhibitors Introduction and Changes of the Other Disease Modifiers’ Drugs in Heart Failure Patients: A Single Center Real World Experience 62
LEAP Virtual Visit Assessment (VIVA): A structured protocol for virtual visits for patients with heart failure 62
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry 61
Endothelial Function Correlates With Pulmonary Pressures in Subjects With Clinically Suspected Pulmonary Hypertension 61
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 61
Acute coronary syndrome with single‑lead ST segment elevation: A rare presentation of multivessel coronary artery disease 59
Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach 59
Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target 58
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 58
Multidisciplinary approach in cardiomyopathies: From genetics to advanced imaging 57
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner? 56
Endothelial Function in Pulmonary Arterial Hypertension: From Bench to Bedside 56
Alcohol consumption and subclinical and clinical coronary heart disease: New insight into potential causal mechanisms 53
SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century? 51
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples 51
Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience 51
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension 49
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients 48
Totale 8.705
Categoria #
all - tutte 56.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.723


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022395 0 2 11 3 70 14 11 38 49 86 6 105
2022/20231.331 117 69 83 38 31 104 2 86 702 10 40 49
2023/2024585 57 18 39 19 79 124 13 94 1 11 14 116
2024/20251.735 88 18 28 77 50 243 159 115 456 153 198 150
2025/20263.844 310 321 444 304 194 186 720 433 316 314 152 150
2026/202772 68 4 0 0 0 0 0 0 0 0 0 0
Totale 9.116